Cytosorbents (CTSO) Other financing activities (2011 - 2026)

Cytosorbents (CTSO) reported Other financing activities of $544000.0 for Q1 2026, down 33.5% on a YoY basis from $818000.0 in Q1 2025, and down 38.6% quarter-over-quarter from $886000.0 in Q4 2025.

Cytosorbents (CTSO) Other financing activities (2011 - 2026) Analysis & Trends

Cytosorbents has reported Other financing activities for 5 years, with the latest figure at $544000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other financing activities fell 33.5% year-over-year to $544000.0; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 204.28% YoY), and the FY2025 full-year result was $2.8 million, down 26.46% from the prior year.
  • Other financing activities for Q1 2026 stood at $544000.0, down from $886000.0 in the prior quarter.
  • The five-year high for Other financing activities was $886000.0 in Q4 2025, with the low at $488000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 Cytosorbents 28.80 Mn 24.00 Mn 6.13 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 544,000.00
Mar 31, 2026 544,000.00
Dec 31, 2025 886,000.00
Dec 31, 2025 886,000.00
Sep 30, 2025 488,000.00
Sep 30, 2025 488,000.00
Jun 30, 2025 571,000.00
Jun 30, 2025 571,000.00
Mar 31, 2025 818,000.00
Mar 31, 2025 818,000.00
Mar 31, 2018 147,988.00
Mar 31, 2018 147,988.00
Jun 30, 2017 1,560.00
Jun 30, 2017 1,560.00
Sep 30, 2011 2,188.00
Sep 30, 2011 2,188.00